Cost-effectiveness of remdesivir and dexamethasone for COVID-19 treatment in South Africa
<p><strong> Background</strong></p> Dexamethasone and remdesivir have the potential to reduce coronavirus disease 2019 (COVID)–related mortality or recovery time, but their cost-effectiveness in countries with limited intensive care resources is unknown. <p><strong&...
Hlavní autoři: | Jo, Y, Jamieson, L, Edoka, I, Long, L, Silal, S, Pulliam, JRC, Moultrie, H, Sanne, I, Meyer-Rath, G, Nichols, BE |
---|---|
Médium: | Journal article |
Jazyk: | English |
Vydáno: |
Oxford University Press
2021
|
Podobné jednotky
-
The role of remdesivir in South Africa: preventing COVID-19 deaths through increasing intensive care unit capacity
Autor: Nichols, BE, a další
Vydáno: (2020) -
The National COVID-19 Epi Model (NCEM): estimating cases, admissions and deaths for the first wave of COVID-19 in South Africa
Autor: Silal, SP, a další
Vydáno: (2023) -
The role of modelling and analytics in South African COVID-19 planning and budgeting
Autor: Meyer-Rath, G, a další
Vydáno: (2023) -
Differential in-hospital mortality and intensive care treatment over time: informing hospital pathways for modelling COVID-19 in South Africa
Autor: Jamieson, L, a další
Vydáno: (2023) -
Inpatient Care Costs of COVID-19 in South Africa’s Public Healthcare System
Autor: Ijeoma Edoka, a další
Vydáno: (2022-08-01)